117 related articles for article (PubMed ID: 20609060)
1. Inhibition of human liver microsomal CYP by nateglinide.
Takanohashi T; Kubo S; Nakayama A; Mihara R; Hayashi M
J Pharm Pharmacol; 2010 May; 62(5):592-7. PubMed ID: 20609060
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies.
Takanohashi T; Koizumi T; Mihara R; Okudaira K
Drug Metab Pharmacokinet; 2007 Dec; 22(6):409-18. PubMed ID: 18159128
[TBL] [Abstract][Full Text] [Related]
3. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
5. Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions.
Lee KS; Kim SK
J Appl Toxicol; 2013 Feb; 33(2):100-8. PubMed ID: 21915887
[TBL] [Abstract][Full Text] [Related]
6. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen AJ
Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
8. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.
Lieu C; Shi J; Donat F; Van Horn R; Brian W; Newton J; Delbressine L; Vos R
Clin Pharmacokinet; 2002; 41 Suppl 2():19-26. PubMed ID: 12383041
[TBL] [Abstract][Full Text] [Related]
9. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
Niemi M; Backman JT; Juntti-Patinen L; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
[TBL] [Abstract][Full Text] [Related]
10. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential.
Furuta S; Akagawa N; Kamada E; Hiyama A; Kawabata Y; Kowata N; Inaba A; Matthews A; Hall M; Kurimoto T
Br J Clin Pharmacol; 2002 Sep; 54(3):295-303. PubMed ID: 12236850
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.
Kim KA; Park JY
Drug Metab Dispos; 2003 Sep; 31(9):1090-2. PubMed ID: 12920163
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
[TBL] [Abstract][Full Text] [Related]
13. A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates.
Liu LY; Han YL; Zhu JH; Yu Q; Yang QJ; Lu J; Guo C
Biomed Chromatogr; 2015 Mar; 29(3):437-44. PubMed ID: 25098274
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes.
Park JY; Kim KA
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):407-9. PubMed ID: 12904931
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
16. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.
Oganesian A; Shilling AD; Young-Sciame R; Tran J; Watanyar A; Azam F; Kao J; Leung L
Psychopharmacol Bull; 2009; 42(2):47-63. PubMed ID: 19629022
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba.
Liu KH; Kim MJ; Jeon BH; Shon JH; Cha IJ; Cho KH; Lee SS; Shin JG
J Clin Pharm Ther; 2006 Feb; 31(1):83-91. PubMed ID: 16476124
[TBL] [Abstract][Full Text] [Related]
18. Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450.
Masek V; Anzenbacherová E; Machová M; Brabec V; Anzenbacher P
Anticancer Drugs; 2009 Jun; 20(5):305-11. PubMed ID: 19378397
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.
Robertson P; DeCory HH; Madan A; Parkinson A
Drug Metab Dispos; 2000 Jun; 28(6):664-71. PubMed ID: 10820139
[TBL] [Abstract][Full Text] [Related]
20. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
